Merus N.V. Announces Pricing of Public Offering of Common Shares

Core Viewpoint - Merus N.V. has announced a public offering of 5,263,158 common shares priced at $57.00 per share, aiming to raise approximately $300 million in gross proceeds to support its oncology product development and general corporate purposes [1][2]. Group 1: Offering Details - The offering includes a 30-day option for underwriters to purchase an additional 789,473 common shares [1]. - The expected closing date for the offering is around June 5, 2025, pending customary closing conditions [2]. - The offering is conducted under a shelf registration statement filed with the SEC, effective since February 28, 2024 [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for advancing clinical development of product candidates, preclinical research, technology development, and general corporate purposes [2]. Group 3: Underwriters - Jefferies, BofA Securities, Leerink Partners, Guggenheim Securities, Truist Securities, and LifeSci Capital are serving as joint book-running managers for the offering, with Van Lanschot Kempen as the lead manager [3]. Group 4: Company Overview - Merus N.V. specializes in developing innovative full-length human bispecific and trispecific antibody therapeutics, known as Multiclonics, which exhibit features similar to conventional human monoclonal antibodies [12].